


Prof. Roland ASMAR
Curriculum vitae

March, 2010

Signature : 
R. ASMAR

Pr Roland Georges ASMAR

Born May 20, 1957
French nationality
Married, three children

11 bis, boulevard Delessert
75016, Paris - France
Tel: +33 6 40 14 22 39

Im. ELMADA
Beit-Mery - Lebanon
Tel : +33 70 23 67 97
E-mail: ra@cmcv.org

CAREER TRAINING, DISTINCTIONS

- Graduation and Doctorate in Medicine (Montpellier University)
- Diploma in Vascular Diseases (French Medical Board)
- Diploma in Cardiology and Vascular Diseases (French Medical Board)
- Diploma in Ultrasound and echocardiography (Créteil University)
- Associated Professor of Medicine (Paris)

- First prize for the Best research work at the European Workshop (Davos, Switzerland)
- First prize of CME in Cardiology for the book : "Ambulatory BP Monitoring"
- First Prize for CME CD Rom on "home BP measurements and hypertension"
- Elected as Cardiologist of the year 2002 in France for the CME activities

- Medal award from the university of Medicine Sendaï- Japan
- Medal award from the Lebanese Medical Board
- Medal award from the Lebanese Ministry of Health
- Medal award from the Chinese Ministry of Health
- Distinction from the Ministry of Health in Dubai, AUE
- Several awards and distinctions from several International Scientific Societies.

TITLES and FUNCTIONS

- President of the "International Society of Vascular Health"
- President of the French-Lebanese Medical Association "AMFL"
- Past Medical Director of the Cardiovascular Institute, Paris
- Past president of the working group on BP of the French Society of Hypertension
- Past president of the "French spoken network of hypertension"
- Member of several boards of International Scientific Societies and journals.

PROFESSIONAL EXPERIENCE

Healthcare

- Assistant at Broussais Hospital, Internal and Vascular Medicine Unit- Paris
- Director of the non-invasive Haemodynamic Unit at Broussais hospital- Paris
- Medical Director of the Cardiovascular Institute - Paris
- Medical Director of the "Clinique Mozart" hospital - Paris
- Consultation & non-invasive investigations in several cardiology & hypertension units
- Primary and secondary cardiovascular prevention.

Clinical Research

- Consultant for several National and International Scientific Societies and Agencies
- Consultant for several pharmaceutical industries and biotechnology manufacturers
- Director of the research unit of the Cardiovascular Institute - Paris
- Research worker in various INSERM units (Institut National de la Santé Et de la Recherche Médicale)
- Conception, coordination and participation to many national and international clinical studies in the fields of : hypertension, arterial stiffness and cardiovascular risk factors
- Setup of 180 investigation centers in different countries for research in the arterial stiffness field (training, equipment and participation to large clinical trials)
- Six Patents (inventor): 4 in the field of arterial stiffness, one in the field of blood pressure measurements and one in the nutrition field for cardiovascular prevention.

Teaching Activities

- Teaching activities in different universities of Medicine in France and other countries
- Continuous Medical Education in different scientific societies and CME associations
- Medical Director of F.C.V (Formation Cardio-Vasculaire) - Paris
- Tutor for physicians participating in international scientific exchange programs
- Director of several theses for Doctorates in Medicine
- Jury members of PhD thesis in French and foreign universities.

SCIENTIFIC MEMBERSHIPS and COMMITTEES

- President of the “International Society of vascular Health” ISVH®
- Member of the European, American, and International Societies of Hypertension
- Honor member of the Algerian society of Hypertension
- Member of editorial or scientific board of several international journals
- Member of different working groups on BP measurements, hypertension and arterial stiffness.

OTHER ACTIVITIES

- Organization of several national and international scientific meetings
- Organization of the First International Consensus Conference on self-blood pressure measurement
- Organization of the first International Consensus Conference on arterial stiffness and its clinical applications.

EDITORIAL ACTIVITY

- Editor in chief of the “Cardiovascular Risk Management journal”
- Member of the editorial board of “Circulation” journal French version
- Publications of many articles in international journals
- Publications of several booklets on “Non-invasive evaluation of cardiovascular haemodynamics”
- Publications of several books, some of them have been edited or translated in different languages: English, French, Chinese, Japanese, Portuguese and Italian.

Publications (Pubmed, Medline indexed)

1. O'Brien E, Atkins N, Stergiou G, Karpettas N, Parati G, Asmar R, Imai Y, Wang J, Mengden T, Shennan A; Working Group on Blood Pressure Monitoring of the European Society of Hypertension. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. *Blood Press Monit* 2010;15(1):23-38.
2. Asmar R, Belghazi J, Khabouth J, Mattar J, Psimenos A, Germano G. Validation of three professional devices measuring office blood pressure according to three different methods: the Omron BP10, the Omron HBP T105 and the Pic Indolor Professional. *J Hypertens* 2010; 28(3): 452-458.
3. Asmar R, El Feghali R, Rejdych M, for the French Investigator Group. Antihypertensive effect of candesartan versus ramipril using ambulatory blood pressure monitoring in hypertensive patients. The Carapas study. *Blood Press J* 2010 (in press)
4. Cremer A, Coulon P, Codjo L, Litalien J, Lemetayer Ph, Coste P, Asmar R, Gosse Ph. Determination of central blood pressure by a non-invasive method (brachial BP and QKD interval). (*submitted*)
5. Codjo L, Coulon P, Cremer A, Litalien J, Lemetayer Ph, Coste P, Asmar R, Gosse Ph. Estimation of central blood pressure from the QKD interval. Validation by a non-invasive method. (*submitted*)
6. Asmar R, Gosse P, Queré S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by amlodipine 5 mg. (*submitted*)
7. Asmar R, Topouchian J, El Feghali R, Pannier B, Koon T, Gao P, on behalf of the TRANS investigators. Arterial stiffness in patients at high cardiovascular risk - the TRAnsced arterial stiffNess Substudy (TRANS study). (*submitted*)
8. Asmar R, Khabouth J, Topouchian J, El Feghali R, Mattar J. Validation of three automatic devices for self-measurement of blood pressure according to the International Protocol: The Omron M3 Intellisense (HEM-7051-E), the Omron M2 Compact (HEM 7102-E), and the Omron R3-I Plus (HEM 6022-E). *Blood Press Monit* 2010;15(1):49-54.
9. Germano G, Psimenos A, Sarullo F, Venditti A, Pecchioli V, Asmar R. Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol: the Pic Indolor Personal Check, Comfort Check, My Check and Travel Check. *Blood Press Suppl* 2009;1:15-23.
10. Postel-Vinay N, Bobrie G, Asmar R. [Patient reporting of self-measurement results: survey Autoprov]. *Rev Prat* 2009;59(8 Suppl):8-12.
11. Sie MP, Yazdanpanah M, Mattace-Raso FU, Uitterlinden AG, Hofman A, Hoeks AP, Reneman RS, Asmar R, Van Duijn CM, Witteman JC. Genetic variation in the renin-angiotensin system and arterial stiffness. The Rotterdam Study. *Clin Exp Hypertens* 2009;31(5):389-99.
12. Halimi JM, Asmar R, Ribstein J. Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. *Diabetes Metab* 2009;35(6):425-30.
13. Asmar R, Hosseini H. Endpoints in clinical trials: does evidence only originate from 'hard' or mortality endpoints? *J Hypertens* 2009;27 Suppl 2:S45-50.
14. Baguet JP, Asmar R, Valensi P, Nisse-Durgeat S, Mallion JM. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. *Vasc Health Risk Manag* 2009;5(1):175-83.

15. Sie MP, Mattace-Raso FU, Uitterlinden AG, Arp PP, Hofman A, Pols HA, Hoeks AP, Reneman RS, Asmar R, van Duijn CM, Witteman JC. The interleukin-6-174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study. *Vasc Health Risk Manag* 2008;4(4):863-9.
16. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet* 2008;372(9644):1174-83.
17. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, O'Brien E, Ohkubo T, Padfield P, Palatini P, Pickering T, Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waeber B, Zanchetti A, Mancia G; ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. *J Hypertens* 2008;26(8):1505-26.
18. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. *Cardiology* 2008;111(4):219-28.
19. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008;358(15):1547-59.
20. Belghazi J, El Feghali RN, Moussalem T, Rejdych M, Asmar RG. Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension. *Vasc Health Risk Manag* 2007;3(4):389-400.
21. Asmar R, Achouba Assya, Brunel P, El Feghali R, Denolle T, Vaisse B. A specific training on hypertension guidelines improves blood pressure control by more than 10% in hypertensive patients : the VALNORM study. *J Am Society Hypertens* 2007;1(4): 278-285.
22. Topouchian J, El Feghali R, Pannier B, Wang S, Zhao F, Smetana K, Teo K, Asmar R. Arterial stiffness and pharmacological interventions—the TRanscend arterial stiffNess Substudy (TRANS study). *Vasc Health Risk Manag* 2007;3(4):381-7.
23. Asmar R, Garcia-Puig J, Gosse P, Karpov YA, De Leeuws PW, Magometschniggs D, Matos L, Schmieder R. Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy. *Vasc Health Risk Manag*. 2007;3(4):371-80.
24. El Féghali R, Nisse-Durgeat S, Asmar R. Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes. *Arch Mal Coeur Vaiss* 2007;100(8):679-82.
25. Asmar R. Blood pressure. Regulation and epidemiology. Standard measures and values. *Nephrol Ther* 2007;3(4):163-84.
26. Valensi P, Baguet JP, Asmar R, Nisse Durgeat S, Mallion JM. Effect of Candesartan Cilexetil on Carotid Intima-Media Thickness in hypertensive type 2 diabetic patients. MITEC Study: Design and baseline characteristics. *Br J Diabetes Vasc Dis* 2007;7:18-24.
27. Féghali RE, Nisse-Durgeat S, Asmar R. Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials. *Vasc Health Risk Manag* 2007;3(1):165-71.
28. Zoungas S, Asmar R. Arterial stiffness and cardiovascular outcome. *Clin Exp Pharmacol Physiol* 2007;34(7):647-51.
29. Asmar R. Fixed-dose combination lercanidipine/enalapril: a viewpoint by Roland Asmar. *Drugs* 2007;67(1):107-108.

30. El Feghali RN, Topouchian JA, Pannier BM, El Assaad HA, Asmar RG; European Society of Hypertension. Validation of the OMRON M7 (HEM-780-E) blood pressure measuring device in a population requiring large cuff use according to the International Protocol of the European Society of Hypertension. *Blood Press Monit* 2007;12(3):173-8.
31. Sie MP, Mattace-Raso FU, Uitterlinden AG, Arp PP, Hofman A, Hoeks AP, Reneman RS, Asmar R, van Duijn CM, Witteman JC. TGF-beta1 polymorphisms and arterial stiffness; the Rotterdam Study. *J Hum Hypertens* 2007;21(6):431-7.
32. El Feghali R, Topouchian J, Pannier B, Asmar R. Ageing and blood pressure modulate the relationship between metabolic syndrome and aortic stiffness in never-treated essential hypertensive patients. A comparative study. *Diabetes Metab* 2007;33(3):183-8.
33. Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion D Jr, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Gallois Y, Amouyel P, Ollivier JP, Asmar R. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. *Am J Hypertens* 2007;20(1):90-7.
34. Scuteri A, Volpe M, Asmar R. Arterial Stiffness and Cognitive Impairment in the Elderly. *High Blood Press Cardiovasc Prev* 2007;14(1):33-37.
35. Asmar R. Effects of pharmacological intervention on arterial stiffness using pulse wave velocity measurement. *J Am Society Hypertens* 2007:104-112.
36. Asmar R. Is quantification of large artery wall properties relevant for the management of hypertension? *Clinical Query. Renin Angiotensin System in Cardiovascular Medicine* 2006;2(3):13-15.
37. Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. *Vasc Health Risk Manag* 2006;2(3):317-23.
38. van Popele NM, Mattace-Raso FU, Vliegenthart R, Grobbee DE, Asmar R, van der Kuip DA, Hofman A, de Feijter PJ, Oudkerk M, Witteman JC. Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study. *J Hypertens* 2006;24(12):2371-6.
39. Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG. Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: the Omron M6 (HEM-7001-E) and the Omron R7 (HEM 637-IT). *Blood Press Monit* 2006;11(3):165-71.
40. Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. *Int J Clin Pract* 2006;60(4):391-8.
41. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. *Int J Clin Pract* 2006;60(3):315-20.
42. Asmar R. Reply. *Am J Hypertens* 2006;19(6):655-656.
43. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. *Circulation* 2006 7;113(5):657-63.
44. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. *Am J Hypertens* 2006;19(1):113-21.
45. Mattace-Raso FU, van der Cammen TJ, van den Elzen AP, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Hofman A, Witteman JC. Moderate alcohol consumption is associated with reduced arterial stiffness in older adults: the Rotterdam study. *J Gerontol A Biol Sci Med Sci* 2005;60(11):1479-83.

46. Topouchian JA, El Assaad MA, Orobinskaia LV, El Feghali RN, Asmar RG. Validation of two devices for self-measurement of brachial blood pressure according to the International Protocol of the European Society of Hypertension: the SEINEX SE-9400 and the Microlife BP 3AC1-1. *Blood Press Monit* 2005;10(6):325-31.
47. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R; COmparative Study of Efficacy of Irbesartan/HCTZ with Valsartan/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. *Am J Hypertens* 2005;18(11):1482-8.
48. Asmar RG. Cardioprotective effects of anti-hypertensive medications. *Curr Med Res Opin* 2005;21 Suppl 5:S17-21.
49. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. *J Hypertens* 2005;23(4):697-701.
50. Parati G, Mendis S, Abegunde D, Asmar R, Mieke S, Murray A, Shengelia B, Steenvoorden G, Van Montfrans G, O'Brien E; World Health Organization. Recommendations for blood pressure measuring devices for office/clinic use in low resource settings. *Blood Press Monit* 2005;10(1):3-10.
51. Sayegh F, Topouchian J, Hlawaty M, Olzewska M, Asmar R. Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients. *Am J Ther* 2005;12(1):3-8.
52. Asmar R, Porcellati C, Dusing R. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison. *Drugs Exp Clin Res* 2004;30(4):153-61.
53. Bahous SA, Stephan A, Barakat W, Blacher J, Asmar R, Safar ME. Aortic pulse wave velocity in renal transplant patients. *Kidney Int* 2004;66(4):1486-92.
54. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, Schalekamp MA, Asmar R, Hofman A, Wittteman JC. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. *Atherosclerosis* 2004;176(1):111-6.
55. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. *J Hypertens* 2004;22(8):1623-30.
56. Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion Júnior D, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Gallois Y, Amouyel P, Ollivier JP, Asmar R. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. *J Hypertens* 2004;22(8):1613-22.
57. Lacourcière Y, Béliveau R, Conter HS, Burgess ED, Lepage S, Pesant Y, Spence JD, Asmar R, Carrière S, Plante GE; Canadian Hypertension Society. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. *Can J Cardiol* 2004;20(8):795-9.
58. Mattace-Raso FU, van der Cammen TJ, Sayed-Tabatabaei FA, van Popele NM, Asmar R, Schalekamp MA, Hofman A, van Duijn CM, Wittteman JC. Angiotensin-converting enzyme gene polymorphism and common carotid stiffness. The Rotterdam study. *Atherosclerosis* 2004;174(1):121-6.
59. Mallion JM, Chamontin B, Asmar R, De Leeuw PW, O'Brien E, Duprez D, O'Rourke MF, Rahn KH, Romero R, Battagay E, Hitzenberger G, Safar ME; REASON Project. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. *Am J Hypertens* 2004;17(3):245-51.

60. Safar ME, Lajemi M, Rudnichi A, Asmar R, Benetos A. Angiotensin-converting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension. *Arterioscler Thromb Vasc Biol* 2004;24(4):782-6.
61. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. *J Am Coll Cardiol* 2004;43(1):92-9.
62. Asmar R. Benefits of blood pressure reduction in elderly patients. *J Hypertens Suppl* 2003;21(6):S25-30.
63. Asmar R, Safar M, Queneau P. Placebo and new therapeutic perspectives for arteriopathy of the lower limbs. *J Mal Vasc* 2003;28(3):117-20.
64. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. *Blood Press Monit* 2003;8(3):127-33.
65. Marre M, Garcia Puig J, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion D Jr, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Pozza G, Chastang C, Ollivier JP, Amouyel P, Asmar R. Effect of indapamide SR on microalbuminuria—the NESTOR study (NatriliX SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)—rationale and protocol for the main trial. *J Hypertens Suppl* 2003;21(1):S19-24.
66. Calvo-Vargas C, Padilla-Rios V, Meza-Flores A, Vazquez-Linares G, Troyo-Sanromán R, Cerda AP, Asmar R. Arterial stiffness and blood pressure self-measurement with loaned equipment. *Am J Hypertens* 2003;16(5 Pt 1):375-80.
67. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens* 2003;21(5):821-48.
68. Asmar R, Safar M, Queneau P. Pulse pressure: an important tool in cardiovascular pharmacology and therapeutics. *Drugs* 2003;63(10):927-32.
69. Asmar R, Gosse P, Topouchian J, N'tela G, Dudley A, Shepherd GL. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. *J Renin Angiotensin Aldosterone Syst* 2002;3(3):176-80.
70. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. *Am J Hypertens* 2002;15(12):1101-8.
71. Pannier B, Guérin A, London G, Asmar R, Safar M; REASON Study. Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study. *Arch Mal Coeur Vaiss* 2002;95 Spec No 6:11-6.
72. Labaki G, Grès CS, Darné B, Bassous M, Asmar R. Green study: quality of blood pressure measurement by general practitioners. *Arch Mal Coeur Vaiss* 2002;95(7-8):713-7.
73. Chemaly E, London G, Benetos A, Darné B, Asmar R. Comparison of central pulse pressure estimated from pulse wave propagation velocity and carotid pulse pressure measured by applanation tonometry. *Arch Mal Coeur Vaiss* 2002;95(7-8):637-40.
74. Gosse P, Dubourg O, Guéret P, De Simone G, Schmieder R, De Leeuw PW, Degaute JP, García Puig J, Karpov Y, Magometschnigg D, Matos L, Amouyel P, Asmar R, Le Heuzey JY, Nieminen M, Dahlöf B. Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular

- hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. *J Hum Hypertens* 2002;16(9):653-9.
75. Queneau P, Asmar R, Safar M. Placebo effect on diastolic, systolic and pulsed arterial pressure. *Presse Med* 2002;31(26):1220-3.
 76. El Assaad MA, Topouchian JA, Darné BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. *Blood Press Monit* 2002;7(4):237-41.
 77. Safar ME, Myers MG, Leenen F, Asmar R. Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. *J Hypertens* 2002;20(8):1653-61.
 78. Asmar R, Pannier B, Vol S, Brisac AM, Tichet J, el Hasnaoui A. Cardiovascular risk factors in France. Prevalence and association. *Arch Mal Coeur Vaiss* 2002;95(4):239-45.
 79. O'Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, Mengden T, Imai Y, Waeber B, Palatini P, Gerin W; Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. *Blood Press Monit* 2002;7(1):3-17.
 80. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J. Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. *Acta Cardiol* 2002;57(1):31-2.
 81. Parati G, Asmar R, Stergiou GS. Self blood pressure monitoring at home by wrist devices: a reliable approach? *J Hypertens* 2002;20(4):573-8.
 82. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. *Hypertension* 2002;39(1):10-5.
 83. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, Thomas F, Pannier B, Asmar R, Zureik M, Safar M, Guize L. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. *Circulation* 2002;105(10):1202-7.
 84. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, Stergiou G, Redón J, Verdecchia P; Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II: blood pressure measurement and cardiovascular outcome. *Blood Press Monit* 2001;6(6):355-70.
 85. Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. *Am J Cardiovasc Drugs* 2001;1(5):387-97.
 86. Asmar R, Darne B, el Assaad M, Topouchian J. Assessment of outcomes other than systolic and diastolic blood pressure: pulse pressure, arterial stiffness and heart rate. *Blood Press Monit* 2001;6(6):329-33.
 87. Asmar R. Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus. *J Renin Angiotensin Aldosterone Syst* 2001;2 Suppl 2:S8-11.
 88. Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, Trimarco B, Fitzgerald D, Hedner T, Duprez D, De Leeuw PW, Sever P, Battagay E, Hitzenberger G, de Luca N, Polónia P, Bénétos A, Chastang C, Ollivier JP, Safar ME; REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOLled double-bliNd Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. *J Hypertens Suppl.* 2001;19(4):S15-20.

89. Asmar R, Mallion JM. CD-ROMs for blood pressure measurement. *Blood Press Monit* 2001;6(4):195-6.
90. Asmar R, Topouchian J, Darne B. Self monitoring versus ambulatory blood pressure monitoring. *Arch Mal Coeur Vaiss* 2001;94(10):1093-8.
91. Asmar RG, London GM, O'Rourke ME, Safar ME; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. *Hypertension* 2001;38(4):922-6.
92. Asmar R, Vol S, Pannier B, Brisac AM, Tichet J, El Hasnaoui A. High blood pressure and associated cardiovascular risk factors in France. *J Hypertens* 2001;19(10):1727-32.
93. Vaïsse B, Ghobrial H, Vaur L, Poncelet P, Asmar R, Herpin D, Mallion JM. Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring. *Arch Mal Coeur Vaiss* 2001;94(8):907-12.
94. Démolis P, Antony I, Asmar R, Carette B, Vaïsse B. REVEIL Trial: Study validity, information and logistics. Preliminary results. Quality measures. *Arch Mal Coeur Vaiss* 2001;94(8):901-5.
95. Antony I, Asmar R, Carette B, Démolis P, Vaïsse B. The REVEIL study: feasibility study of blood pressure self-monitoring. Preliminary results and patient opinions. *Arch Mal Coeur Vaiss* 2001;94(8):897-900.
96. Asmar R, Nisse-Durgeat S, el Assaad M, Topouchian J, Amah G, Darné B. Quality of blood pressure measurement in the management of arterial hypertension. Pilot study. *Arch Mal Coeur Vaiss* 2001;94(8):885-8.
97. Asmar R. Measuring arterial hypertension. *J Med Liban* 2000;48(6):347-53.
98. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. *Am J Hypertens* 2001;14(6 Pt 1):546-52.
99. Asmar R, Vol S, Brisac AM, Tichet J, Topouchian J. Reference values for clinic pulse pressure in a nonselected population. *Am J Hypertens* 2001;14(5 Pt 1):415-8.
100. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension* 2001;37(5):1236-41.
101. Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T; Effect Study Group. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. *Blood Press* 2001;10(1):43-51.
102. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M; Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. *J Hypertens*. 2001;19(4):813-8.
103. Smulyan H, Asmar RG, Rudnicki A, London GM, Safar ME. Comparative effects of aging in men and women on the properties of the arterial tree. *J Am Coll Cardiol* 2001;37(5):1374-80.
104. Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, Cambien F, Benetos A. Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. *J Hypertens* 2001;19(3):407-13.
105. Asmar R, Rudnicki A, Blacher J, London GM, Safar ME. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. *Am J Hypertens*. 2001;14(2):91-7.
106. Hornyk A, Marre M, Mimran A, Chaignon M, Asmar R, Fauvel JP; Groupe Evaluation de la Société française d'hypertension artérielle de la mesure. Microalbuminuria in arterial hypertension.

- Measurement, variables, interpretation, recommendations. *Arch Mal Coeur Vaiss* 2000;93(11):1304-8.
107. Asmar R. Measuring arterial pressure. *Arch Mal Coeur Vaiss* 2000;93(11 Suppl):1363-70.
 108. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Hoeks AP, van der Kuip DA, Hofman A, Witteman JC. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. *Stroke* 2001;32(2):454-60.
 109. Blacher J, Fournier V, Asmar R, Guerin AP, Pannier B, Safar ME, London GM. Aortic Pulse Wave Velocity as a Marker of Atherosclerosis in Hypertension. *CVR & R* 2001; 431: 420-42.
 110. Asmar R, Lacourcière Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. *J Hypertens* 2000;18(11):1683-90.
 111. Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure. *J Hypertens* 2000;18(9):1159-63.
 112. de Gaudemaris R, Asmar R, Girerd X, Mallion JM, Maitre A. Validation of electronic automatic-measurement arterial blood pressure devices. *Arch Mal Coeur Vaiss* 2000;93(8):979-82.
 113. Benetos A, Guize L, Rudnichi A, Safar M, Asmar R, Bean K. How can hypertensive patients be better treated? The contribution of combination therapy. *J Cardiovasc Pharmacol.* 2000;35 Suppl 3:S13-16.
 114. Denolle T, Waeber B, Kjeldsen S, Parati G, Wilson M, Asmar R. Self-measurement of blood pressure in clinical trials and therapeutic applications. *Blood Press Monit* 2000;5(2):145-9.
 115. Asmar R. Proceedings from the first international consensus conference on self-blood pressure measurement. *Blood Press Monit* 2000;5(2):91-2.
 116. Asmar R, Zanchetti A. Guidelines for the use of self-blood pressure monitoring: a summary report of the First International Consensus Conference. Groupe Evaluation & Measure of the French Society of Hypertension. *J Hypertens* 2000;18(5):493-508.
 117. Ribeiro L, Gama G, Santos A, Asmar R, Martins L, Polónia J. Arterial distensibility in subjects with white-coat hypertension with and without diabetes or dyslipidaemia: comparison with normotensives and sustained hypertensives. *Blood Press Monit* 2000;5(1):11-7.
 118. Myers MG, Asmar R, Leenen FH, Safar M. Fixed low-dose combination therapy in hypertension—a dose response study of perindopril and indapamide. *J Hypertens* 2000;18(3):317-25.
 119. Albaladejo P, Asmar R, Safar M, Benetos A. Association between 24-hour ambulatory heart rate and arterial stiffness. *J Hum Hypertens* 2000;14(2):137-41.
 120. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. *Am J Hypertens* 1999;12(12 Pt 1-2):1181-7.
 121. White WB, Asmar R, Imai Y, Mansoor GA, Padfield P, Thijs L, Waeber B. Task force VI: Self-monitoring of the blood pressure. *Blood Press Monit* 1999;4(6):343-51.
 122. Asmar R, Amah G, Crisan O, Haddad S. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. *Eur Heart J* 1999;1(suppl P):P21-30.
 123. Blacher J, Mourad JJ, Asmar R, Girerd X, London G, Safar M. Value of arterial rigidity measurements in cardiovascular pathology. *Ann Cardiol Angeiol (Paris)* 1999;48(4):264-7.
 124. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. *Hypertension* 1999;34(4 Pt 2):837-42.

125. Asmar RG. Noninvasive evaluation of arterial abnormalities in hypertensive patients. *Pathol Biol (Paris)* 1999;47(7):685-95.
126. Asmar R, Topouchian J, Potocka AC, Pannier B, Rudnichi A, Safar M. Evaluation of the effect of an antihypertensive treatment on arterial distensibility in essential arterial hypertension. The Complior study. A preliminary analysis of data at inclusion. *Arch Mal Coeur Vaiss* 1999;92(8):949-55.
127. Asmar R, Topouchian J, Potocka AC, Rudnichi A, Safar M. Complior study: preliminary analysis of data at inclusion. *J Hypertens* 1999;17(6):848-849.
128. Ferreira AV, Viana MC, Mill JG, Asmar RG, Cunha RS. Racial differences in aortic stiffness in normotensive and hypertensive adults. *J Hypertens* 1999;17(5):631-7.
129. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. *Hypertension* 1999;33(5):1111-7.
130. Topouchian J, Asmar R, Sayegh F, Rudnicki A, Benetos A, Bacri AM, Safar ME. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. *Stroke* 1999;30(5):1056-64.
131. Hornyk A, Asmar R. Microalbuminuria and arterial hypertension. *Presse Med* 1999 20;28(11):597-604.
132. Mallion JM, Asmar R, Boutelant S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. *J Cardiovasc Pharmacol* 1998;32(4):673-8.
133. Asmar R, Madonna O, Brisac AM, Benetos A, Laurent S. Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists. *Therapie* 1998;53(3):253-70.
134. Asmar R. Efficacy and safety of indapamide 1.5 mg sustained release coated tablets in the therapy of arterial hypertension. *Ann Cardiol Angeiol (Paris)* 1998;47(2):94-104.
135. Asmar R. Cardiovascular risk and ambulatory blood pressure measurement of arterial pressure. *Ann Cardiol Angeiol (Paris)* 1998;47(2):75-80.
136. Safar ME, London GM, Asmar R, Frohlich ED. Recent advances on large arteries in hypertension. *Hypertension* 1998;32(1):156-61.
137. Topouchian J, Brisac AM, Pannier B, Vicaut E, Safar M, Asmar R. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double-blind, comparative and crossover study. *J Hum Hypertens* 1998;12(3):181-7.
138. Rudnichi A, Safar M, Asmar R, Guize L, Benetos A. Prevalence of cardiovascular risk factors in a French population. *J Hypertens Suppl* 1998;16(1):S85-90.
139. Asmar R, Brisac AM, Courivaud JM, Lecor B, London GM, Safar ME. Influence of gender on the level of pulse pressure: the role of large conduit arteries. *Clin Exp Hypertens* 1997;19(5-6):793-811.
140. Assessment of antihypertensive effect by blood pressure monitoring: applications to bisoprolol and lisinopril in a double-blind study. Vaisse B, Herpin D, Asmar R, Battistella P, Zannad F, Boutelant S, Lyon A, Conte D, Denis J, Honore P, Contard S, Prost PL, Mallion JM, Poggi L. *J Cardiovasc Pharmacol* 1997;29(5):612-7.
141. Asmar RG, Topouchian JA, Benetos A, Sayegh FA, Mourad JJ, Safar ME. Non-invasive evaluation of arterial abnormalities in hypertensive patients. *J Hypertens Suppl* 1997;15(2):S99-107.
142. Large artery stiffness in hypertension. Benetos A, Laurent S, Asmar RG, Lacolley P. *J Hypertens Suppl* 1997;15(2):S89-97.

143. Benetos A, Cambien F, Gautier S, Ricard S, Safar M, Laurent S, Lacolley P, Poirier O, Topouchian J, Asmar R. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. *Hypertension* 1996;28(6):1081-4.
144. Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, Madonna O, Safar M, Giudicelli JF, Gajdos P. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. *Circulation* 1996;94(6):1316-24.
145. Mallion JM, Asmar R, Ambrosioni E, MacMahon M, Coupez JM, de Cordoüe A, Barrandon S, Brault Y, Guez D, Safar M. Evaluation of trough/peak ratio of indapamide 1.5 mg sustained-release form assessed by ambulatory blood pressure monitoring. *Arch Mal Coeur Vaiss* 1996;89 Spec No 4:27-38.
146. Asmar R, Scuteri A, Topouchian J, Brisac AM, Maldonado J, Cloarec L, Safar M. Arterial distensibility and circadian blood pressure variability. *Blood Press Monit* 1996;1:333-8.
147. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, Larosa E, Guize L, Safar M, Soubrier F, Cambien F. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. *Circulation* 1996;94(4):698-703.
148. Asmar R, Brisac AM, Sayegh F, Khalil Z, Safar M. Family physicians and scientific information. Survey on hypertension and diuretics. *Arch Mal Coeur Vaiss* 1996;89(8):1081-5.
149. Asmar R, Waeber B. Assessment of antihypertensive efficacy by non-invasive ambulatory blood pressure monitoring. *Blood Press Monit* 1996;1(3):307.
150. Asmar R. Therapeutic efficacy. *Blood Press Monit* 1996;1(3):305-306.
151. Asmar R, Boutelant S, Chaignon M, Guedon J, Topouchian J, Mallion JM, Safar M. Repeated measurements of non-invasive ambulatory blood pressure: distinction between reproducibility and the proper effect of placebo. *Blood Press Monit* 1996;1(3):283-288.
152. Asmar R, Benetos A, Pannier B, Agnes E, Topouchian J, Laloux B, Safar M. Prevalence and circadian variations of ST-segment depression and its concomitant blood pressure changes in asymptomatic systemic hypertension. *Am J Cardiol* 1996 15;77(5):384-90.
153. Bénétos A, Laflèche A, Asmar R, Gautier S, Safar A, Safar ME. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. *J Hum Hypertens* 1996;10(2):77-82.
154. Siche JP, Herpin D, Asmar RG, Poncelet P, Chamontin B, Comparat V, Gressin V, Boutelant S, Mallion JM. Non-invasive ambulatory blood pressure variability and cardiac baroreflex sensitivity. *J Hypertens* 1995;13(12 Pt 2):1654-9.
155. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. *Hypertension* 1995;26(3):485-90.
156. Andrzejak M, Mallion JM, Asmar R, Chau NG, de Gaudemaris R, Drici M, Herpin D, Poncelet P. Ambulatory blood pressure monitoring and clinical trials. *Arch Mal Coeur Vaiss* 1995;88(8):1175-8.
157. Asmar R, Guez D, Malbezin M, Brault Y, de Cordoue A, Barrandon S, Bruxelles MC, Chastang C. Therapeutic benefit of a low dose of indapamide: results of a double-blind against placebo European controlled study. *Arch Mal Coeur Vaiss* 1995;88(8):1083-7.
158. Benetos A, Topouchian J, Ricard S, Gautier S, Bonnardeaux A, Asmar R, Poirier O, Soubrier F, Safar M, Cambien F. Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. *Hypertension* 1995;26(1):44-7.

159. Cunha RS, Benetos A, Laurent S, Safar ME, Asmar RG. Distension capacity of the carotid artery and ambulatory blood pressure monitoring. Effects of age and hypertension. *Am J Hypertens* 1995;8(4 Pt 1):343-52.
160. Asmar R, Safavian A, Tual JL, Safar ME. Arterial and cardiac changes in hypertension in the elderly. *Blood Press Suppl.* 1995;3:31-7.
161. Asmar R, Benetos A, London G, Hugue C, Weiss Y, Topouchian J, Laloux B, Safar M. Aortic distensibility in normotensive, untreated and treated hypertensive patients. *Blood Press* 1995;4(1):48-54.
162. Laurent S, Becquemont L, Laloux B, Asmar R, Hugue C, Vayssairat M, Billaud E, Bauthier P, Cohen N, Houri L, et al. Hemodynamic effects of chronic treatment by cilazapril in normotensive patients with obliterative arterial diseases of the lower limbs. *Arch Mal Coeur Vaiss* 1994;87(8):987-90.
163. Benetos A, Asmar R, Gautier S, Salvi P, Safar M. Heterogeneity of the arterial tree in essential hypertension: a noninvasive study of the terminal aorta and the common carotid artery. *J Hum Hypertens* 1994;8(7):501-7.
164. Asmar RG, Julia PL, Mascarel VL, Fabiani JN, Benetos A, Safar ME. Ambulatory blood pressure profile after carotid endarterectomy in patients with ischaemic arterial disease. *J Hypertens* 1994;12(6):697-702.
165. Safar ME, Asmar R, Benetos A, Levy BI, London GM. Sodium, large arteries, and diuretic compounds in hypertension. *Am J Med Sci* 1994;307 Suppl 1:S3-8.
166. Asmar R, Benetos A, Ghodsi N, Meilhac B, Safar M. Regional arterial hemodynamics and carotid circulation in essential arterial hypertension. Effect of nitrendipine in patients over 40 years of age. *Presse Med* 1993;22(35):1770-5.
167. Asmar RG, Benetos A, Chaouche-Teyara K, Raveau-Landon CM, Safar ME. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. *Am J Cardiol* 1993;72(11):794-8.
168. Poggi L, Mallion JM, Renucci JF, Vaïsse B, de Gaudemaris R, Chanudet X, Asmar R, Tcherdakoff P. Non-invasive ambulatory measurement of arterial pressure. Recommendations of the measurement group of the French Society of Arterial Hypertension. *Arch Mal Coeur Vaiss* 1993;86(8):1137-42.
169. Asmar R, Benetos A, Brahimi M, Chaouche K, Safar M. Arterial and antihypertensive effects of nitrendipine: a double-blind comparison versus placebo. *J Cardiovasc Pharmacol* 1992;20(6):858-63.
170. Asmar RG, Benetos A, Darne BM, Pauly NC, Safar ME. Converting enzyme inhibition: dissociation between antihypertensive and arterial effects. *J Hum Hypertens* 1992;6(5):381-5.
171. Herpin D, Vaïsse B, Raud-Raynier P, Boijoux C, Pitiot M, Asmar R, Contard S, Gosse P, de Gaudemaris R, Zannad F, et al. Comparative effects of angiotensin converting enzyme inhibitors and calcium inhibitors related to baseline ambulatory blood pressure. A French multicenter study. *Arch Mal Coeur Vaiss* 1992;85(8):1235-8.
172. Safar ME, Asmar RG, Benetos A, London GM, Lévy BI. Sodium, large arteries and diuretic compounds in hypertension. *J Hypertens Suppl.* 1992;10(6):S133-6.
173. Asmar RG, Iannascoli F, Benetos A, Safar ME. Dose optimization study of arterial changes associated with angiotensin converting enzyme inhibition in hypertension. *J Hypertens Suppl.* 1992;10(5):S13-9.
174. Safar ME, Asmar RG, Benetos A. Large artery dilation produced by converting enzyme inhibition in hypertension: therapeutic aspects. *Am J Med* 1992;92(4B):47S-53S.
175. Asmar RG, Girerd XJ, Brahimi M, Safavian A, Safar ME. Ambulatory blood pressure measurement, smoking and abnormalities of glucose and lipid metabolism in essential hypertension. *J Hypertens* 1992;10(2):181-7.

176. Asmar RG, Benetos A, Darne B, Laurent S, Safar ME. An indirect evaluation of the effect of the autonomic nervous system following converting enzyme inhibition in hypertension. *Clin Exp Hypertens A*;14(5):853-73.
177. Asmar RG, Pannier BM, London GM, Safar ME. Cardiac hypertrophy and arterial compliance after antihypertensive treatment. *Arch Mal Coeur Vaiss* 1991;84 Spec No 4:79-83.
178. Demolis PD, Asmar RG, Levy BI, Safar ME. Non-invasive evaluation of the conduit function and the buffering function of large arteries in man. *Clin Physiol* 1991;11(6):553-64.
179. Thomas JR, Asmar RG, Safar ME. Effects of perindopril on structural and functional changes in hypertensive arteries. *S Afr Med J* 1991;Suppl:6-9.
180. Benetos A, Asmar R, Vasmant D, Thiéry P, Safar M. Long lasting arterial effects of the ACE inhibitor ramipril. *J Hum Hypertens* 1991;5(5):363-8.
181. Girerd X, Laurent S, Pannier B, Asmar R, Safar M. Arterial distensibility and left ventricular hypertrophy in patients with sustained essential hypertension. *Am Heart J* 1991;122(4 Pt 2):1210-4.
182. Asmar R, Boulanger P, Benetos A, Darne B, Laurent S, Safar M. Antihypertensive efficacy of the combination of captopril 50mg and hydrochlorothiazide 25mg evaluated by ambulatory blood pressure measurement. *Presse Med* 1991;20(26):1215-8.
183. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. *Am J Cardiol* 1991;68(1):61-4.
184. Asmar R, Sassano P, Demolis P, Ménard J, Safar M. Validation of Oscillomat, a device for self-measurement of blood pressure. Comparison with mercury sphygmomanometers. *Presse Med* 1991;20(12):551-5.
185. Asmar RG, Pannier BM, London GM, Safar ME. Cardiac hypertrophy and arterial compliance following drug treatment in hypertension. *J Cardiovasc Pharmacol* 1991;18 Suppl 7:S37-9.
186. Asmar RG, Pannier B, Laurent ST, Benetos A, Daou J, Safar M. Haemodynamic effects of perindopril in essential hypertension. *J Hum Hypertens* 1990;4 Suppl 4:35-43.
187. Demolis P, Asmar R, Lévy B, Manent PJ, Safar M. Non-invasive study of hemodynamics in peripheral arteries by pulsed Doppler associated with bidimensional echography. A preliminary study. *Arch Mal Coeur Vaiss* 1990;83(8):1335-41.
188. Laurent S, Asmar R, Pannier B, London G, Safar M. Methods for studying vasodilator agents in arterial hypertension. *Arch Mal Coeur Vaiss* 1990;83 Spec No 2:69-73.
189. Djian J, Fermé I, Zannad F, Chaignon M, Asmar R. Effects of sustained-release diltiazem on blood pressure and serum lipids: a multicenter, randomized, placebo-controlled study. *J Cardiovasc Pharmacol* 1990;16 Suppl 1:S38-45.
190. Benetos A, Levy B, Asmar R, Safar M. Hemodynamic effects of perindopril. *Ann Cardiol Angeiol (Paris)* 1989;38(7 Pt 2):483-6.
191. Van Viet H, De Jaeger C, Chevalier P, Asmar R, Leylavergne J, Safar M, Rullière R. False and true hypertension in the aged subject. Diagnostic errors and potential solutions. *Presse Med* 1989;18(26):1293-6.
192. Mallion JM, Asmar R, Poggi L, Safar M, André JL, Balansard P, Barrala A, Battaglia C, Boutarin JB, Chaignon M, et al. Arterial pressure: self measurement. Recommendations. French Society for Arterial Hypertension—the Measurement Group. *Arch Mal Coeur Vaiss* 1989;82(7):1001-5.
193. Santoni JP, Asmar RG, Bizot-Espiard JG, Safar M. Ambulatory registration of arterial pressure during treatment with perindopril. Effects on systolic pressure and hemodynamic implications. *Arch Mal Coeur Vaiss* 1989;82 Spec No 1:51-6.

194. Santoni JP, Asmar R, Safar ME. Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension. *Clin Exp Hypertens A*. 1989;11 Suppl 2:535-44.
195. Asmar RG, Pannier BM, Santoni JP, Safar ME. Angiotensin converting enzyme inhibition decreases systolic blood pressure more than diastolic pressure as shown by ambulatory blood pressure monitoring. *J Hypertens Suppl*. 1988;6(3):S79-81.
196. Asmar RG, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, Levy BI, Safar ME. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. *J Hypertens Suppl*. 1988;6(3):S33-9.
197. Vaisse B, de Gaudemaris R, Asmar R, Poggi L, Mallion JM, Safar M. Non-invasive ambulatory blood pressure measurement over 24 hours: effects of labetalol on the rise of blood pressure in the early morning. *Ann Cardiol Angeiol (Paris)* 1988;37(10):621-6.
198. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. *Circulation* 1988;78(4):941-50.
199. Raison JM, Safar ME, Asmar RE, Achimastos AM, London GM. Sex dependence of body fat distribution and fluid volumes in hypertension. *Kidney Int Suppl*. 1988;25:S122-4.
200. Asmar RG, Safar ME, Santoni JP, Pannier BM, London GM. Enhanced brachial artery compliance following perindopril in essential hypertension. *Am J Hypertens* 1988;1(3 Pt 3):103S-105S.
201. Pannier B, Brunel P, Laurent S, Asmar R, Safar M. Pulse pressure and echocardiographic parameters in essential arterial hypertension. *Arch Mal Coeur Vaiss* 1988;81 Spec No:33-7.
202. Brunel P, Asmar R, Pannier B, Laurent S, Safar M. Pulse wave velocity and ambulatory blood pressure in essential arterial hypertension. *Arch Mal Coeur Vaiss* 1988;81 Spec No:235-9.
203. Asmar RG, Brunel PC, Pannier BM, Lacolley PJ, Safar ME. Arterial distensibility and ambulatory blood pressure monitoring in essential hypertension. *Am J Cardiol* 1988;61(13):1066-70.
204. Hugues CJ, Asmar RG, London GM, Safar ME. Age- and sex-related changes in the ratio between ankle and brachial systolic pressure in normal subjects. *Angiology* 1988;39(3 Pt 1):219-26.
205. Safar M, Asmar R, Bouthier J, Lacolley P, Laurent S. Converting enzyme inhibition and the common carotid circulation in older patients with sustained essential hypertension. *Eur Heart J* 1988;9 Suppl D:75-8.
206. Hugue CJ, Safar ME, Aliefierakis MC, Asmar RG, London GM. The ratio between ankle and brachial systolic pressure in patients with sustained uncomplicated essential hypertension. *Clin Sci (Lond)* 1988;74(2):179-82.
207. Safar M, Laurent S, Safavian A, Pannier B, Asmar R. Sodium and large arteries in hypertension. Effects of indapamide. *Am J Med* 1988;84(1B):15-9.
208. Asmar R, Hugues C, Pannier B, Daou J, Safar ME. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. *Eur Heart J* 1987;8 Suppl M:115-20.
209. Brunel P, Asmar R, Pannier B, Safar M. Comparison between the ambulatory and occasional determination of the blood pressure. *Ann Cardiol Angeiol (Paris)* 1987;36(8):393-7.
210. Pannier B, Asmar R, Laurent S, London G, Safar M. Index of arterial and venous compliance and echocardiographic parameters in essential permanent arterial hypertension. *Arch Mal Coeur Vaiss* 1987;80(6):879-82.

211. Asmar R, Safar M, Santoni J, Pannier B, London G. Forearm arterial haemodynamics following concerting enzyme inhibition by perindopril in essential hypertension. *J Hypertens* 1987;5(suppl5):S169-S171.
212. Safar ME, Totomoukouo JJ, Asmar RA, Laurent SM. Increased pulse pressure in patients with arteriosclerosis obliterans of the lower limbs. *Arteriosclerosis* 1987;7(3):232-7.
213. Safar ME, Laurent S, Asmar RE, Safavian A, London GM. Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. *Angiology* 1987;38(4):287-95.
214. Asmar RG, Pannier BM, Hugue CJ, Laurent S, Safavian A, Safar ME. Captopril + hydrochlorothiazide 24 h ambulatory monitoring effects. *Br J Clin Pharmacol* 1987;23 Suppl 1:77S-81S.
215. Safar ME, Toto-Moukouo JJ, Bouthier JA, Asmar RE, Levenson JA, Simon AC, London GM. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment. *Circulation* 1987;75(1 Pt 2):I156-61.
216. Safar ME, Laurent S, Asmar RA, Hugue CJ, London GM. Cardiac hypertrophy and aortic distensibility in essential hypertension. *J Cardiovasc Pharmacol* 1987;10 Suppl 6:S86-90.
217. Safar ME, London GM, Asmar RG, Hugues CJ, Laurent SA. An indirect approach for the study of the elastic modulus of the brachial artery in patients with essential hypertension. *Cardiovasc Res* 1986;20(8):563-7.
218. Toto-Moukouo JJ, Achimastos A, Asmar RG, Hugues CJ, Safar ME. Pulse wave velocity in patients with obesity and hypertension. *Am Heart J* 1986;112(1):136-40.
219. Raison J, Achimastos A, Asmar R, Simon A, Safar M. Extracellular and interstitial fluid volume in obesity with and without associated systemic hypertension. *Am J Cardiol* 1986;57(4):223-6.
220. Bouthier J, Hugue C, Asmar R, Simon A, Safar M. The renin-angiotensin system and large arteries in the hypertensive patient. *Ann Cardiol Angeiol (Paris)* 1985;34(10):693-6.
221. Toto-Moukouo J, Asmar R, Safar M. Use of exercise testing in the evaluation of patients with borderline hypertension. *Practical Cardiology* 1984; 10:61-66.

Other publications

1. Asmar R. Arterial Stiffness and pulse wave velocity. Clinical applications. China. People's Military Medical Press Ed., 2005
2. Asmar R, Maldonado J. O Placebo na Pratica Clinica. IIFC ed., 2002
3. Asmar R, Hugue C, Safar M. Les tableaux cliniques de l'HTA et ses retentissements. In : Prise en charge de l'Hypertension Artérielle. Global Santé, 2001
4. Asmar R, Benetos A, de Champlain J et al. Physiopathologie et méthodes de mesure de la pression artérielle. In : Prise en charge de l'Hypertension Artérielle. Global Santé, 2000
5. Asmar R. Hypertension artérielle et pression pulsée. Global Santé, 2000
6. Asmar R. Arterial Stiffness and pulse wave velocity. Clinical applications. Elsevier Ed., 1999
7. Asmar R. Mesure ambulatoire de la pression artérielle. Au-delà de la PA, le couple Cœur-Artère. Astra, 1999
8. Asmar R, Maldonado J. Medição Ambulatoria da Pressao Arterial na Pratica Clinica. Delta ed., 1999
9. Asmar R. Le système artériel. Unité et diversité. Lederle, 1998

10. Asmar R, Maldonado J. Medição da Pressao Arterial. Delta ed., 1998
11. Asmar R, Mallion JJ. La pression artérielle : mesure, variations, interprétations, recommandations. Maloine Imhotep, 1997.
12. Asmar R. Le Doppler continu artériel en pratique clinique. Parke-Davis, 1996
13. Asmar R. Guida all'Esame Ecografico del Sistema Vascolare Arterioso. Piccin Ed., 1994
14. Asmar R. Guida all'Esame Doppler del Sistema Vascolare Arterioso. Piccin Ed., 1994
15. Asmar R. Guida all'Esame Doppler del Sistema Vascolare Arterioso. Piccin Ed., 1993
16. Asmar R. Mesure Ambulatoire de la Pression Artérielle en pratique clinique. Simep-Masson Ed., 1992
17. Asmar R, Germano G. Le modificazioni della Pressione Arterioso. Masson Ed., 1991
18. Asmar R. Méthodes de mesure de la Pression Artérielle. Springer Verlag. Paris, 1991
19. Asmar R. Atlas de la Mesure Ambulatoire de la Pression Artérielle. Parke-Davis Ed., 1990
20. Asmar R, Mienville G. Automesure de la pression artérielle. Mallez Ed., 1990
21. Safar M, Asmar R, Benetos A, Hugue C, Laflèche A, Laurent S, Pannier B. Système artériel et pression artérielle. Du concept à la pratique. Pil Ed., 1989
22. Safar M, Soubies P, Safavian A, Asmar R, Laurent S. Antihypertensive therapy with uncontrolled systolic pressure and increased aortic rigidity. In: How should elderly hypertensive patients be treated? Omae T and Zanchetti A Eds. Springer-Verlag (Tokyo, London, Paris, New York) 1989; 143-150
23. Safar M, Asmar R, Benetos A, Hugue Ch, Laflèche A, Laurent S, Pannier B. Système artériel et pression artérielle : du concept à la pratique. PIL Ed. Paris, 1989
24. Asmar R. Une technique d'exploration artérielle : le Doppler vasculaire. Specia, 1987
25. Asmar R, Chaignon, Dallochio, Debru et al. La pression artérielle en ambulatoire. Edilux Ed., 1987
